Everolimus

Pharm Company: * WEST-WARD PHARMS INT
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Everolimus Overview

Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR). It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers. It is marketed by Novartis under the trade names Zortress (USA) ...

Read more Everolimus Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Everolimus

Recent Everolimus Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Everolimus: (3 results)

Sorted by National Drug Code

• 49884-119 Everolimus 2.5 mg Oral Tablet by Par Pharmaceutical, Inc.
• 49884-125 Everolimus 5 mg Oral Tablet by Par Pharmaceutical, Inc.
• 49884-127 Everolimus 7.5 mg Oral Tablet by Par Pharmaceutical, Inc.

Other drugs which contain Everolimus or a similar ingredient: (4 results)

• AFINITOR Everolimus3 discussions
• AFINITOR DISPERZ Everolimus
• CERTICAN Everolimus
• ZORTRESS Everolimus

Related Everolimus Topics: